Skip to content

Internet-administrated Treatment of Anxiety Disorders

Tailored Internet-administrated Treatment of Anxiety Disorders - A Randomised Controlled Trial (NOVA II)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01390168
Acronym
NOVA II
Enrollment
100
Registered
2011-07-08
Start date
2010-01-31
Completion date
2012-12-31
Last updated
2013-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Disorders, Depression

Brief summary

The purpose of this study is to determine whether tailored internet-administered cbt is a feasible treatment for anxiety disorders in clinical settings.

Interventions

This intervention contains up to 6-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.

BEHAVIORALWaitlist

active waitlist

Sponsors

Umeå University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* over 18 years * fulfill the criteria for at least one anxiety syndrome

Exclusion criteria

* ongoing psychological treatment * suicidal prone * ongoing alcohol addiction

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in Clinical Outcome in Routine Evaluation - Outcome Measure (CORE-OM)Two weeks pre treatment (baseline), two weeks post treatment, and 12 months post treatmentMeasures anxiety and depressive symptoms. Change from baseline in anxiety and depressive symptoms expected between time frames.

Secondary

MeasureTime frameDescription
Change from baseline in Beck Anxiety Inventory (BAI)Two weeks pre treatment (baseline), two weeks post treatment, 12 months post treatmentMeasures anxiety symtoms. Change from baseline in anxiety symptoms expected between time frames.
Change from baseline in Montgomery Åsberg Depression Rating Scale-Self Rated (MADRS-S)Two weeks pre treatment (baseline), two weeks post treatment, and 12 months post treatmentMeasures depressive symptoms. Change from baseline in depressive symptoms expected between time frames.
Change from baseline in Quality of Life Inventory (QOLI)Two weeks pre treatment (baseline), two weeks post treatment, and 12 months post treatmentMeasures quality of life. Change from baseline in quality of life expected between time frames.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 27, 2026